IGC PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
IGC PHARMA, INC. (IGC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.55% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-14
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 4.27%.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 3.93%, a 5.30% decline year-over-year.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-06-30 was 4.15%, a 57.20% increase year-over-year.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-06-30 was 2.64%, a 0.00% change year-over-year.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.93%, a 25.00% decline from fiscal 2024.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 5.24%, a 116.53% increase from fiscal 2023.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 2.42%, a 0.00% change from fiscal 2022.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.42%, a 255.88% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 4.55% 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | 4.27% 10-Q · filed 2026-05-15 | |||||
| 2025-12-31 | 4.14% 10-KT · filed 2026-03-18 | 5.24% 10-Q · filed 2026-08-14 | ||||
| 2025-09-30 | 4.01% 10-Q · filed 2025-11-14 | |||||
| 2025-06-30 | 3.93% 10-Q · filed 2025-08-14 | |||||
| 2025-03-31 | 3.93% 10-KT · filed 2026-03-18 | |||||
| 2024-12-31 | 4.49% 10-Q · filed 2025-02-14 | |||||
| 2024-09-30 | 4.15% 10-Q · filed 2024-11-12 | |||||
| 2024-06-30 | 4.15% 10-Q · filed 2024-08-07 | |||||
| 2024-03-31 | 5.24% 10-K · filed 2025-06-27 | |||||
| 2023-12-31 | 4.15% 10-Q · filed 2024-02-14 | |||||
| 2023-09-30 | 3.49% 10-Q · filed 2023-11-09 | |||||
| 2023-06-30 | 2.64% 10-Q · filed 2023-08-10 | |||||
| 2023-03-31 | 2.42% 10-K · filed 2024-06-24 | 3.49% 10-K · filed 2023-07-07 | ||||
| 2022-12-31 | 2.64% 10-Q · filed 2023-02-14 | |||||
| 2022-09-30 | 2.64% 10-Q · filed 2022-11-01 | |||||
| 2022-06-30 | 2.64% 10-Q · filed 2022-08-05 | |||||
| 2022-03-31 | 2.42% 10-K · filed 2023-07-07 | |||||
| 2021-12-31 | 1.61% 10-Q · filed 2022-02-10 | |||||
| 2021-09-30 | 1.61% 10-Q · filed 2021-10-29 | |||||
| 2021-06-30 | 1.61% 10-Q · filed 2021-08-11 | |||||
| 2021-03-31 | 0.68% 10-K · filed 2022-06-23 | |||||
| 2020-12-31 | 0.68% 10-Q · filed 2022-02-10 | |||||
| 2020-09-30 | 0.68% 10-Q · filed 2021-10-29 | |||||
| 2020-06-30 | 0.68% 10-Q · filed 2021-08-11 | 2.57% 10-Q · filed 2020-08-19 | ||||
| 2020-03-31 | 2.57% 10-K · filed 2021-06-14 | |||||
| 2019-12-31 | 2.57% 10-Q · filed 2021-02-16 | |||||
| 2019-09-30 | 2.57% 10-Q · filed 2020-11-20 | |||||
| 2019-06-30 | 2.57% 10-Q · filed 2020-08-19 | |||||
| 2019-03-31 | 0.70% 10-K · filed 2020-07-13 | |||||
| 2018-12-31 | 0.70% 10-Q · filed 2020-02-10 | |||||
| 2018-09-30 | 0.70% 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | 0.70% 10-Q · filed 2019-08-09 | |||||
| 2018-03-31 | 0.70% 10-K · filed 2019-06-14 | |||||
| 2017-03-31 | 0.70% 10-K · filed 2017-07-14 | |||||
| 2014-03-31 | 1.98% 10-K · filed 2014-07-15 | |||||
| 2013-03-31 | 4.10% 10-K · filed 2014-07-15 | |||||
| 2011-06-30 | 4.10% 10-K · filed 2016-07-14 | |||||
| 2010-03-31 | 1.98% 10-K · filed 2015-07-14 | |||||
| 2009-12-31 | 1.98% 10-K · filed 2014-07-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |